Pharsight

Secuado patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10583121 HISAMITSU Patch
Jul, 2033

(9 years from now)

US10814002 HISAMITSU Patch and method for producing the same
Jul, 2033

(9 years from now)

US9687474 HISAMITSU Patch
Jul, 2033

(9 years from now)

US10022445 HISAMITSU Patch
Jul, 2033

(9 years from now)

US11123305 HISAMITSU Patch
Jul, 2033

(9 years from now)

US11813364 HISAMITSU Patch
Sep, 2033

(9 years from now)

Secuado is owned by Hisamitsu.

Secuado contains Asenapine.

Secuado has a total of 6 drug patents out of which 0 drug patents have expired.

Secuado was authorised for market use on 11 October, 2019.

Secuado is available in system;transdermal dosage forms.

Secuado can be used as method of treating adults with schizophrenia comprising administering asenapine via a transdermal patch.

The generics of Secuado are possible to be released after 22 September, 2033.

Drug Exclusivity Drug Exclusivity Expiration
New Product (NP) Oct 11, 2022

Drugs and Companies using ASENAPINE ingredient

Market Authorisation Date: 11 October, 2019

Treatment: Method of treating adults with schizophrenia comprising administering asenapine via a transdermal patch

Dosage: SYSTEM;TRANSDERMAL

More Information on Dosage

SECUADO family patents

Family Patents